Ginny Kosor serves as the Executive Director of Facilities Operations at FibroGen, where she leverages her extensive twenty years of management experience to drive strategic initiatives in the pharmaceutical industry. With a robust background in clinical laboratories, medical devices, and biological companies, Ginny is recognized...
Ginny Kosor serves as the Executive Director of Facilities Operations at FibroGen, where she leverages her extensive twenty years of management experience to drive strategic initiatives in the pharmaceutical industry. With a robust background in clinical laboratories, medical devices, and biological companies, Ginny is recognized for her exceptional leadership skills and her ability to build cohesive teams that excel in high-pressure environments. Currently, she is spearheading the construction of an Oral Solid Dose Pilot Facility in Beijing, China, a pivotal project that underscores her expertise in facilities management and project management within the context of Good Manufacturing Practices (GMP).
Under her guidance, the project has not only adhered to stringent regulatory requirements but has also achieved the critical Pharmaceutical Product Pipeline (PPP) designation, showcasing her commitment to quality assurance and operational excellence. Ginny's strategic vision is complemented by her hands-on experience in technology transfer and standard operating procedures (SOP), which ensures that the facility will meet the highest industry standards upon completion. Her proficiency in decision-making and troubleshooting has been instrumental in navigating the complexities of facility design and construction, particularly in a global context.
As a thought leader in the pharmaceutical sector, Ginny Kosor continues to influence the landscape of facilities operations, fostering innovation while maintaining a steadfast focus on compliance and quality. Her multifaceted skill set, combined with her passion for advancing healthcare solutions, positions her as a key player in FibroGen's mission to deliver transformative therapies to patients worldwide.
